Core Insights - Coherus Oncology has expanded its clinical program for CHS-114, a selective Treg depleter, to include colorectal cancer, addressing a significant unmet medical need [1][2] - The company reported a net revenue of $11.2 million for LOQTORZI in Q3 2025, marking a 12% increase from Q2 2025 and a 92% increase from Q3 2024 [5][8] - As of September 30, 2025, Coherus had cash, cash equivalents, and marketable securities totaling $191.7 million [16] Recent Business Highlights - LOQTORZI is the only FDA-approved treatment for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma in the U.S. [5] - The growth in LOQTORZI's revenue is attributed to increased patient demand and awareness of updated NCCN guidelines [5] - The company is focusing on expanding its oncology pipeline, including combining LOQTORZI with internal candidates like CHS-114 and casdozokitug [4][19] Financial Performance - For Q3 2025, net revenue from continuing operations was $11.6 million, compared to $6.1 million in Q3 2024, and $29.4 million for the nine months ended September 30, 2025, compared to $18.7 million in the same period of 2024 [8][14] - Research and development expenses increased to $27.3 million in Q3 2025 from $22.1 million in Q3 2024, driven by the development of casdozokitug and CHS-114 [10] - The net loss from continuing operations for Q3 2025 was $44.5 million, a slight improvement from a net loss of $47.6 million in Q3 2024 [14][15] Pipeline Developments - CHS-114 is currently in Phase 1b/2a studies targeting various cancers, including head and neck squamous cell carcinoma and colorectal cancer [21] - Casdozokitug is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma, showing promising monotherapy activity in treatment-refractory non-small cell lung cancer [7][21] - Initial data readouts for ongoing studies are expected throughout 2026, indicating a robust pipeline for the company [2][11]

Core Insights - Crescent Biopharma, Inc. is focused on advancing innovative therapies for cancer patients, with a pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates [2] Company Overview - Crescent Biopharma aims to become a leading oncology company by developing transformative therapies for solid tumors, utilizing multiple modalities and established targets [2] Upcoming Events - The company will present at the Cantor Global Healthcare Conference on September 4, 2025, and at the Morgan Stanley Annual Global Healthcare Conference on September 8, 2025 [3]

Core Viewpoint - Apollomics Inc. reported financial results for the fiscal year ended December 31, 2024, highlighting its focus on developing oncology drug candidates, particularly vebreltinib, and its strategic collaborations to enhance clinical data and market opportunities [1][9]. Financial Results - As of December 31, 2024, Apollomics had $9.8 million in cash and cash equivalents, a decrease from $37.8 million in 2023 [12]. - The net loss for 2024 was $(53.9) million, or $(52.80) per basic and diluted share, compared to a net loss of $(172.6) million, or $(231.99) per share in 2023 [12][20]. - Research and development expenses for 2024 were $24.6 million, down from $34.2 million in 2023 [12][20]. - Administrative expenses decreased to $17.8 million in 2024 from $20.6 million in 2023 [12][20]. Pipeline and Clinical Updates - Apollomics is focusing on vebreltinib (APL-101), a c-Met inhibitor, which has shown a 43% objective response rate in a Phase 2 clinical trial for non-CNS MET fusion solid tumors [6]. - The company announced a strategic collaboration with LaunXP to develop vebreltinib in combination with an EGFR inhibitor, which includes a $10 million upfront payment and potential milestone payments of up to $50 million [5][12]. - New interim data for vebreltinib includes promising results for treating NSCLC with MET amplification and non-CNS solid tumors with MET fusions [5][6]. Business Highlights - Apollomics raised $5.8 million in a private placement in May 2024 [12]. - The company has terminated collaborations with Glycomimetics and TYG Oncology to focus resources on vebreltinib MET amplification [12]. - The strategic focus on vebreltinib aims to address the unmet medical needs of patients with specific c-Met alterations [12].